Products - Skin cancer | Topic | NICE

Showing 3 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC